Article | September 11, 2019

The Good Data Submission Doctor: Should I Stay Or Should I Go?

Source: Cytel

By Angelo Tinazzi, Sr. Director, Standards, Systems, CDISC Consulting, Statistical Programming, Cytel Inc.

Questions

A recurring question we get from our clients is whether it is worth adopting data standards such as CDISC in the early phase of their drug development, and if it is worth spending more to produce SDTM and ADaM packages at an early stage. This question is usually a concern of small biotech not wanting to "risk" money without knowing (yet) the future of their compound.

It's an easy question (for me) to answer: yes it is worth adopting the standards from the very beginning for the following five main reasons:

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: